APLS

Apellis Pharmaceuticals
APLS

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$2.20B
EV
$2.25B
Shares Outstanding
125.52M
Beta
0.84

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$42.20
P/E 2025E
-
P/Revenue 2025E
2.55x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Apellis Pharmaceuticals, Inc.

gainify
APLS

Apellis Pharmaceuticals, Inc.

APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAV...

Sector

Healthcare

Industry

Biotechnology

CEO

Francois, Cedric

Employees

708

IPO Date

2017-11-09

Headquarters

100 Fifth Avenue, Waltham, Massachusetts, 02451, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved